The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Michael H. Davidson

Radiant Research

515 N. State St.

Suite 2700




Name/email consistency: high



  • Radiant Research, 515 N. State St., Suite 2700, Chicago, USA. 2006 - 2012
  • The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, USA. 2007 - 2011
  • Department of Medicine, Section of Cardiology, Pritzker School of Medicine, University of Chicago, USA. 2005 - 2011
  • Rush University Medical Center, Chicago, Illinois 60612, USA. 2003 - 2009
  • University of Chicago Pritzker, USA. 2009
  • Rush University Medical Center, 1725 West Harrison St, Ste 1159, Chicago, USA. 2006 - 2007
  • Department of Preventive Cardiology, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Chicago, USA. 2003 - 2006
  • Department of Cardiology, Rush University Medical College, 60610, USA. 2006
  • Radiant Research, Chicago, USA. 2006


  1. Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. Davidson, M., Rosenson, R.S., Maki, K.C., Nicholls, S.J., Ballantyne, C.M., Setze, C., Carlson, D.M., Stolzenbach, J. Cardiovasc. Drugs. Ther (2012) [Pubmed]
  2. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. Davidson, M.H. J. Clin. Lipidol (2011) [Pubmed]
  3. Focusing on high-density lipoprotein for coronary heart disease risk reduction. Davidson, M.H. Cardiol. Clin (2011) [Pubmed]
  4. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Davidson, M.H. Curr. Atheroscler. Rep (2011) [Pubmed]
  5. Update on CETP inhibition. Davidson, M.H. J. Clin. Lipidol (2010) [Pubmed]
  6. Should niacin be the preferred drug to add to a statin? Davidson, M.H. Curr. Cardiol. Rep (2010) [Pubmed]
  7. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Davidson, M.H., Donovan, J.M., Misir, S., Jones, M.R. Am. J. Cardiovasc. Drugs (2010) [Pubmed]
  8. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. Davidson, M.H. J. Clin. Lipidol (2010) [Pubmed]
  9. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Davidson, M.H., Rooney, M.W., Drucker, J., Eugene Griffin, H., Oosman, S., Beckert, M. Clin. Ther (2009) [Pubmed]
  10. Apolipoprotein measurements: is more widespread use clinically indicated? Davidson, M.H. Clin. Cardiol (2009) [Pubmed]
  11. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Davidson, M.H., Rosenson, R.S. Am. J. Cardiol. (2009) [Pubmed]
  12. Focus on HDL as a therapeutic target for CAD risk reduction. Davidson, M.H. Am. J. Cardiol. (2009) [Pubmed]
  13. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Davidson, M.H. Curr. Atheroscler. Rep (2009) [Pubmed]
  14. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Davidson, M.H., Gandhi, S.K., Ohsfeldt, R.L., Fox, K.M. Am. J. Med. (2009) [Pubmed]
  15. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Davidson, M.H., Maki, K.C., Dicklin, M.R., Feinstein, S.B., Witchger, M., Bell, M., McGuire, D.K., Provost, J.C., Liker, H., Aviram, M. Am. J. Cardiol. (2009) [Pubmed]
  16. AURORA and JUPITER trials: recognizing the limitations and expanding the benefits of statin treatment. Davidson, M.H. Curr. Cardiol. Rep (2009) [Pubmed]
  17. An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time. Davidson, M.H. J. Fam. Pract (2009) [Pubmed]
  18. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Davidson, M. Am. J. Cardiol. (2008) [Pubmed]
  19. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Davidson, M.H. Cleve. Clin. J. Med (2008) [Pubmed]
  20. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Davidson, M.H., Corson, M.A., Alberts, M.J., Anderson, J.L., Gorelick, P.B., Jones, P.H., Lerman, A., McConnell, J.P., Weintraub, H.S. Am. J. Cardiol. (2008) [Pubmed]
  21. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Davidson, M.H., Jones, P.H. Clin. Drug. Investig (2008) [Pubmed]
  22. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Davidson, M.H. Am. J. Cardiol. (2008) [Pubmed]
  23. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. Davidson, M.H., Ballantyne, C.M. Am. J. Cardiol. (2008) [Pubmed]
  24. Atherosclerosis surrogate imaging trials come of age: for better or for worse? Davidson, M.H., Dembowski, E. Curr. Cardiol. Rep (2008) [Pubmed]
  25. Introduction. U.S. incidence of coronary artery disease. Davidson, M.H. Am. J. Cardiol. (2008) [Pubmed]
  26. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Davidson, M.H. Expert. Opin. Pharmacother (2007) [Pubmed]
  27. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Davidson, M.H. Am. J. Manag. Care (2007) [Pubmed]
  28. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Davidson, M.H., Stein, E.A., Bays, H.E., Maki, K.C., Doyle, R.T., Shalwitz, R.A., Ballantyne, C.M., Ginsberg, H.N. Clin. Ther (2007) [Pubmed]
  29. Global risk management in patients with type 2 diabetes mellitus. Davidson, M.H. Am. J. Cardiol. (2007) [Pubmed]
  30. Rosuvastatin in elderly patients. Davidson, M.H. Drugs. Aging (2007) [Pubmed]
  31. Safety of aggressive lipid management. Davidson, M.H., Robinson, J.G. J. Am. Coll. Cardiol. (2007) [Pubmed]
  32. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Davidson, M.H. Am. Heart. Hosp. J (2007) [Pubmed]
  33. High-density lipoprotein metabolism: potential therapeutic targets. Davidson, M.H., Toth, P.P. Am. J. Cardiol. (2007) [Pubmed]
  34. Squalene synthase inhibition: a novel target for the management of dyslipidemia. Davidson, M.H. Curr. Atheroscler. Rep (2007) [Pubmed]
  35. Safety considerations with fibrate therapy. Davidson, M.H., Armani, A., McKenney, J.M., Jacobson, T.A. Am. J. Cardiol. (2007) [Pubmed]
  36. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Davidson, M.H. Expert. Opin. Drug. Saf (2006) [Pubmed]
  37. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Davidson, M.H., Maccubbin, D., Stepanavage, M., Strony, J., Musliner, T. Am. J. Cardiol. (2006) [Pubmed]
  38. Statin safety: an appraisal from the adverse event reporting system. Davidson, M.H., Clark, J.A., Glass, L.M., Kanumalla, A. Am. J. Cardiol. (2006) [Pubmed]
  39. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Davidson, M.H., Bays, H.E., Stein, E., Maki, K.C., Shalwitz, R.A., Doyle, R. Clin. Cardiol (2006) [Pubmed]
  40. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Davidson, M.H. Am. J. Cardiol. (2006) [Pubmed]
  41. Lipid-lowering effects of statins: a comparative review. Davidson, M.H., Robinson, J.G. Expert. Opin. Pharmacother (2006) [Pubmed]
  42. Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?. Davidson, M.H. Nature Clinical Practice. Cardiovascular Medicine (2006) [Pubmed]
  43. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. Davidson, M.H., McKenney, J.M., Shear, C.L., Revkin, J.H. J. Am. Coll. Cardiol. (2006) [Pubmed]
  44. Differences between clinical trial efficacy and real-world effectiveness. Davidson, M.H. Am. J. Manag. Care (2006) [Pubmed]
  45. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Davidson, M.H., Maki, K.C., Pearson, T.A., Pasternak, R.C., Deedwania, P.C., McKenney, J.M., Fonarow, G.C., Maron, D.J., Ansell, B.J., Clark, L.T., Ballantyne, C.M. Am. J. Cardiol. (2005) [Pubmed]
  46. Management of dyslipidemia in patients with complicated metabolic syndrome. Davidson, M.H. Am. J. Cardiol. (2005) [Pubmed]
  47. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Davidson, M.H., Bays, H., Rhyne, J., Stein, E., Rotenberg, K., Doyle, R. Clin. Ther (2005) [Pubmed]
  48. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Davidson, M. Prev. Cardiol (2005) [Pubmed]
  49. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Davidson, M.H. Am. J. Cardiol. (2005) [Pubmed]
  50. Biologic therapies for dyslipidemia. Davidson, M.H. Curr. Atheroscler. Rep (2004) [Pubmed]
  51. Combination therapy in the management of complex dyslipidemias. Davidson, M.H., Toth, P.P. Curr. Opin. Lipidol. (2004) [Pubmed]
  52. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Davidson, M.H., Ballantyne, C.M., Kerzner, B., Melani, L., Sager, P.T., Lipka, L., Strony, J., Suresh, R., Veltri, E. Int. J. Clin. Pract. (2004) [Pubmed]
  53. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Davidson, M.H. Expert. Opin. Drug. Saf (2004) [Pubmed]
  54. Comparative effects of lipid-lowering therapies. Davidson, M.H., Toth, P.P. Prog. Cardiovasc. Dis (2004) [Pubmed]
  55. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Davidson, M.H. Curr. Atheroscler. Rep (2003) [Pubmed]
  56. Newer pharmaceutical agents to treat lipid disorders. Davidson, M.H. Curr. Cardiol. Rep (2003) [Pubmed]
  57. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Davidson, M.H., Palmisano, J., Wilson, H., Liss, C., Dicklin, M.R. Clin. Ther (2003) [Pubmed]
WikiGenes - Universities